MCID: CLS016
MIFTS: 49

Clostridium Difficile Colitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Clostridium Difficile Colitis

MalaCards integrated aliases for Clostridium Difficile Colitis:

Name: Clostridium Difficile Colitis 12 54 15 70
Pseudomembranous Colitis 12 70
Enterocolitis, Pseudomembranous 44
Clostridium Difficile Infection 70
Pseudomembranous Enterocolitis 17
Colitis Pseudomembranous 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0060185
MeSH 44 D004761
NCIt 50 C128347
ICD10 32 A04.7
UMLS 70 C0014358 C0085819 C0238106 more

Summaries for Clostridium Difficile Colitis

Disease Ontology : 12 A colitis characterized by an overgrowth of Clostridium difficile bacteria.

MalaCards based summary : Clostridium Difficile Colitis, also known as pseudomembranous colitis, is related to reactive arthritis and peptic ulcer disease, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Clostridium Difficile Colitis is IL1B (Interleukin 1 Beta), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Rifaximin and Teicoplanin have been mentioned in the context of this disorder. Affiliated tissues include colon, spinal cord and skin, and related phenotype is homeostasis/metabolism.

Related Diseases for Clostridium Difficile Colitis

Diseases related to Clostridium Difficile Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 473)
# Related Disease Score Top Affiliating Genes
1 reactive arthritis 30.5 LTF IL1B CRP CCR6
2 peptic ulcer disease 30.3 IL1B ATP4A ATP12A
3 intestinal obstruction 30.3 CRP ATP4A ATP12A ALB
4 amebiasis 30.3 LEPR IL1B ALB
5 blind loop syndrome 30.2 ATP4A ATP12A ALB
6 appendicitis 30.2 IL1B CRP ALB
7 prosthetic joint infection 30.2 IL1B CRP
8 bacterial infectious disease 30.2 LTF IL1B CRP CCR6
9 disease by infectious agent 30.1 IL1B CRP CCR6 ALB
10 proctitis 30.0 LTF CRP CCR6
11 gastroenteritis 30.0 IL1B CRP ALB
12 paralytic ileus 30.0 CRP ATP4A ATP12A ALB
13 toxic megacolon 30.0 RHOD RHOBTB1 CRP CCR6 ATP4A ATP12A
14 cellulitis 30.0 CRP CCR6 ALB
15 otitis media 29.9 IL1B CRP ALB
16 constipation 29.9 CRP CDC42 ATP4A ATP12A ALB
17 adult-onset still's disease 29.9 IL1RAPL2 IL1B CRP
18 dysentery 29.9 IL1RAPL2 IL1B CRP CCR6 ATP4A ATP12A
19 acquired immunodeficiency syndrome 29.8 IL1B CRP CCR6 ALB
20 kawasaki disease 29.8 IL1B CRP ALB
21 diverticulitis 29.8 CRP CCR6 ATP4A ATP12A ALB
22 chickenpox 29.8 CRP CCR6 ALB
23 volvulus of midgut 29.8 CRP ATP4A ATP12A ALB
24 aspiration pneumonitis 29.8 CRP ATP4A ATP12A ALB
25 aspiration pneumonia 29.8 CRP ATP4A ATP12A ALB
26 pericarditis 29.8 IL1B CRP ALB
27 perinatal necrotizing enterocolitis 29.7 LTF IL1B CRP CCR6 ALB
28 gastrointestinal tuberculosis 29.7 CRP ALB
29 crohn's disease 29.7 LTF IL1B CRP CCR6 ALB
30 acute cystitis 29.6 IL1B CRP CCR6 ALB
31 endocarditis 29.6 TPI1 CRP ALB
32 celiac disease 1 29.4 IL1B CRP CCR6 ATP4A ATP12A ALB
33 colitis 11.3
34 chemical colitis 11.2
35 diarrhea 11.0
36 megacolon 10.8
37 peritonitis 10.6
38 ileus 10.5
39 enterocolitis 10.5
40 acute kidney failure 10.4
41 ulcerative colitis 10.4
42 cystic fibrosis 10.4
43 urinary tract infection 10.4
44 hemolytic-uremic syndrome 10.4
45 toxic shock syndrome 10.4
46 vagus nerve disease 10.4 ATP4A ATP12A
47 scalp dermatosis 10.4 ATP4A ATP12A
48 hemangioma of intra-abdominal structure 10.4 ATP4A ATP12A
49 acquired gastric outlet stenosis 10.4 ATP4A ATP12A
50 lingual goiter 10.4 ATP4A ATP12A

Graphical network of the top 20 diseases related to Clostridium Difficile Colitis:



Diseases related to Clostridium Difficile Colitis

Symptoms & Phenotypes for Clostridium Difficile Colitis

UMLS symptoms related to Clostridium Difficile Colitis:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

MGI Mouse Phenotypes related to Clostridium Difficile Colitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.47 ALB ATP12A ATP4A CCR6 CRP IL1B

Drugs & Therapeutics for Clostridium Difficile Colitis

Drugs for Clostridium Difficile Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
2
Teicoplanin Approved, Investigational Phase 4 61036-62-2
3
Vancomycin Approved Phase 4 1404-90-6 441141 14969
4 Polyethylene glycol 3350 Phase 4
5 Cathartics Phase 4
6 Laxatives Phase 4
7 Vitamins Phase 4
8 Cola Phase 4
9 Immunosuppressive Agents Phase 4
10
Pantoprazole Approved Phase 3 102625-70-7 4679
11
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
12
Rifampicin Approved Phase 3 13292-46-1 5458213 5381226
13
Glycerol Approved, Investigational Phase 3 56-81-5 753
14
Varespladib methyl Investigational Phase 3 172733-08-3
15 Proton Pump Inhibitors Phase 3
16 Antitubercular Agents Phase 3
17 Oxazolidinones Phase 3
18 Immunoglobulins Phase 3
19 Antibodies Phase 3
20 Antibodies, Monoclonal Phase 3
21 Pharmaceutical Solutions Phase 2, Phase 3
22 Antiparasitic Agents Phase 2, Phase 3
23 Antiprotozoal Agents Phase 2, Phase 3
24 Vaccines Phase 3
25
Ceftriaxone Approved Phase 2 73384-59-5 5479530 5361919
26
Iron Approved Phase 2 7439-89-6 23925 29936
27
Titanium dioxide Approved Phase 2 13463-67-7
28
Misoprostol Approved Phase 2 59122-46-2 5282381
29
Coal tar Approved Phase 2 8007-45-2
30
Trichostatin A Experimental Phase 2 58880-19-6
31 Immunologic Factors Phase 2
32 glutamine Phase 2
33 Hormones Phase 2
34 Calcium, Dietary Phase 2
35 Calcium Aluminosilicate Phase 2
36
Calcium Nutraceutical Phase 2 7440-70-2 271
37
Omeprazole Approved, Investigational, Vet_approved Phase 1 73590-58-6 4594
38
Aluminum sulfate Approved Phase 1 10043-01-3
39 Tin Fluorides Phase 1
40
Histamine Approved, Investigational 51-45-6, 75614-87-8 774
41 Barley Approved
42
Ethanol Approved 64-17-5 702
43
Inulin Approved, Investigational, Nutraceutical 9005-80-5 24763
44 Histamine H2 Antagonists
45
Histamine Phosphate 51-74-1 65513
46 Charcoal
47 Fluoroquinolones
48 Immunoglobulin A
49 Rho(D) Immune Globulin
50 Immunoglobulins, Intravenous

Interventional clinical trials:

(show top 50) (show all 199)
# Name Status NCT ID Phase Drugs
1 Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection Unknown status NCT02237859 Phase 4 Vancomycin
2 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
3 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics Completed NCT02951702 Phase 4 Vancomycin Oral
4 An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus Vancomycin Completed NCT01818141 Phase 4 Vancomycin;Fidaxomicin
5 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
6 A Randomised Placebo Controlled Trial of "Follow on" Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
7 A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population Completed NCT02254967 Phase 4 Fidaxomicin;Vancomycin
8 A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections Recruiting NCT02692651 Phase 4 Fidaxomicin;Vancomycin
9 Prospective, Interventional, Phase IV Study, Evaluating the Efficacy and Safety of Teicoplanin (100-200 mg, Administered Orally Twice a Day) in Patients With Clostridium Difficile Infection-associated Diarrhea and Colitis Recruiting NCT04003818 Phase 4 TEICOPLANIN
10 A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Recruiting NCT04000555 Phase 4 Oral Vancomycin
11 Screening to Prophylax Against Clostridium Difficile Infection Recruiting NCT02996487 Phase 4 Vancomycin
12 Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection Recruiting NCT04138706 Phase 4 Vancomycin;Placebos
13 Historically-controlled Clinical Trial of the Efficacy and Safety of Bezlotoxumab (BEZLO) in Addition to Standard of Care (SOC) Vancomycin for the Treatment of Multi-recurrent Clostridium Difficile Infection (CDI) Recruiting NCT03880539 Phase 4 bezlotoxumab;Vancomycin Oral
14 CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection Recruiting NCT02667418 Phase 4 Fidaxomicin;Vancomycin with Taper/Pulse;Vancomycin
15 Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD). Recruiting NCT04626947 Phase 4
16 Efficacy of Prophylactic Oral Vancomycin in Preventing Recurrent Clostridium Difficile Infection in Hospitalized Patients Requiring Antibiotics Active, not recruiting NCT03466502 Phase 4 Oral Vancomycin
17 Double Blinded, Randomized Controlled Trial of Oral Vancomycin Versus Placebo in Hospitalized Patients With Diarrhea and Stool toXin NEGative But Nucleic Acid Amplification Test Positive for Toxigenic Clostridium Difficile (TOX NEG Trial) Active, not recruiting NCT03388268 Phase 4 Oral Vancomycin;Placebo
18 Fecal Microbiota Transplant Enrolling by invitation NCT04090346 Phase 4
19 Secondary Prophylaxis With Oral Vancomycin for Clostridium Difficile Recurrence: A Randomized Control Study Enrolling by invitation NCT03200093 Phase 4 Oral Vancomycin;Placebo
20 Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study Not yet recruiting NCT04415918 Phase 4 Bezlotoxumab Injection
21 Study of the Efficacy of Loperamide in Treating Patients for Clostridium Difficile Colitis and Diarrheal Disease of Unknown Cause Associated With Prior Antibiotic Therapy. Suspended NCT00591357 Phase 4 loperamide;placebo
22 Protocol CHUM 2014-5056: A Randomized, Double Blinded Placebo Controlled Study to Evaluate the Efficacy of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea in Hospitalized Patients Terminated NCT01972932 Phase 4
23 Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
24 A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy Terminated NCT01775397 Phase 4 Fidaxomicin;Vancomycin;Placebo
25 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
26 Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection Withdrawn NCT02464306 Phase 4 fidaxomicin
27 The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients Withdrawn NCT01552668 Phase 4 Fidaxomicin;Placebo
28 Can Use of Bismuth Subsalicylate in Clostridium Difficile Patients Decrease the Length of Stay and Time to Resolution of Symptoms Withdrawn NCT03592082 Phase 4 Bismuth Subsalicylate;standard antibiotic therapy
29 Addition of a Probiotic (Lactobacillus GG) to Metronidazole for the Treatment of Clostridium Difficile Associated Disease Withdrawn NCT00304863 Phase 4 Lactobacillus GG
30 Transplantation of Fecal Microbiota for Clostridium Difficile Infection Unknown status NCT01958463 Phase 3
31 Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections Unknown status NCT02774382 Phase 3 Vancomycin;Fecal microbiota transplantation;Rectal bacteriotherapy
32 Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU Completed NCT02290327 Phase 3 Pantoprazole;Placebo
33 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy Completed NCT00304356 Phase 3 Nitazoxanide
34 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY II) Completed NCT01513239 Phase 3 SOC
35 Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection Completed NCT02743234 Phase 3 Fidaxomicin;Vancomycin
36 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I) Completed NCT01241552 Phase 3 SOC
37 A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection Completed NCT03244644 Phase 3 RBX2660;Placebo
38 A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea Completed NCT01597505 Phase 3 Surotomycin;Vancomycin;Placebo
39 A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea Completed NCT01598311 Phase 3 CB-183,315;Vancomycin;Placebo
40 A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD). Completed NCT01983683 Phase 3 Cadazolid;Vancomycin;Cadazolid-matching placebo;Vancomycin-matching placebo
41 A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD) Completed NCT01987895 Phase 3 Cadazolid;Vancomycin;Cadazolid-matching placebo;Vancomycin-matching placebo
42 A Prospective, Multi-center, Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule vs Colonoscopy in the Management of Recurrent Clostridium Difficile Infection (CDI) Completed NCT02254811 Phase 2, Phase 3
43 A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea Completed NCT00106509 Phase 3 tolevamer potassium-sodium (GT267-004)
44 Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD) Completed NCT00182429 Phase 3 Metronidazole and Rifampin
45 A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3 Tolevamer potassium-sodium (GT267-004)
46 COmparative Effectiveness of intestinaL microbiOta Versus vaNcomycin for Primary c. Difficile Infection - randomiZEd Trials Recruiting NCT03796650 Phase 3 Vancomycin
47 A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile Infection Recruiting NCT03931941 Phase 3 RBX2660
48 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III) Recruiting NCT03182907 Phase 3 Placebo
49 CSP #2004 - Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) Recruiting NCT03005379 Phase 2, Phase 3 Fecal Microbiota Therapy (FMT);Placebo
50 Prospective, Open-label Trial to Evaluate Efficacy of 30-day Duration of Fidaxomicin in Patients With Recurrent C. Difficile Infection Recruiting NCT02395848 Phase 3 Fidaxomicin

Search NIH Clinical Center for Clostridium Difficile Colitis

Cochrane evidence based reviews: enterocolitis, pseudomembranous

Genetic Tests for Clostridium Difficile Colitis

Anatomical Context for Clostridium Difficile Colitis

MalaCards organs/tissues related to Clostridium Difficile Colitis:

40
Colon, Spinal Cord, Skin, Kidney, Bone, Heart, Neutrophil

Publications for Clostridium Difficile Colitis

Articles related to Clostridium Difficile Colitis:

(show top 50) (show all 2261)
# Title Authors PMID Year
1
Cytosolic delivery and characterization of the TcdB glucosylating domain by using a heterologous protein fusion. 61 54
11119561 2001
2
Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. 54 61
9384296 1997
3
Effects of Clostridium difficile toxin A and toxin B on phospholipase D activation in human promyelocytic leukemic HL60 cells. 61 54
8890188 1996
4
The cytotoxic effect of Clostridioides difficile pore-forming toxin CDTb. 61
33689753 2021
5
Reactive arthritis: an unusual presentation of acute Clostridioides difficile colitis. 61
33795278 2021
6
Establishing causality in Salmonella-microbiota-host interaction: The use of gnotobiotic mouse models and synthetic microbial communities. 61
33756190 2021
7
New ribotype Clostridioides difficile from ST11 group revealed higher pathogenic ability than RT078. 61
33682630 2021
8
Determining the optimal surgical timing of fulminant Clostridium difficile colitis by using four objective factors and computed tomography findings: A case report. 61
33609944 2021
9
Circumferential esophageal perforation resulting in tension hydropneumothorax in a patient with septic shock. 61
33691378 2021
10
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. 61
33540694 2021
11
Prevalence and phylogenetic relationship of Clostridioides difficile strains in fresh poultry meat samples processed in different cutting plants. 61
33388709 2021
12
Atypical Hemolytic Uremic Syndrome in the Setting of Acute Clostridium difficile Colitis. 61
33728192 2021
13
Histopathology of Non-IBD Colitis. A practical approach from the Italian Group for the study of the gastrointestinal tract (GIPAD). 61
33686310 2021
14
Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. 61
33469019 2021
15
Functional analyses of epidemic Clostridioides difficile toxin B variants reveal their divergence in utilizing receptors and inducing pathology. 61
33507919 2021
16
Severe Clostridium difficile infection with extremely high leucocytosis complicated by a concomitant bloodstream infection caused by Klebsiella pneumoniae after osteomyelitis surgery: A case report. 61
33352444 2021
17
Toxic Clostridioides (formerly Clostridium) difficile colitis: No longer a diarrhea associated infection. 61
32680621 2021
18
Concomitant Vancomycin-Resistant Enterococcus faecium and Clostridium difficile Colitis. 61
33790728 2021
19
Clostridium Difficile and COVID-19: Novel Risk Factors for Acute Portal Vein Thrombosis. 61
33728091 2021
20
Emergency department frequentation and unscheduled readmissions within the first year after liver transplantation, and their impact on survival. 61
33486960 2021
21
Peptidoglycan analysis reveals that synergistic deacetylase activity in vegetative Clostridium difficile impacts the host response. 61
33453911 2020
22
Peptidoglycan analysis reveals that synergistic deacetylase activity in vegetative Clostridium difficile impacts the host response. 61
32978253 2020
23
Development of a Standardized Scoring System to Assess a Murine Model of Clostridium difficile Colitis. 61
30892111 2020
24
Uncommon Case of Oral Vancomycin Neurotoxicity With Sexual Dysfunction. 61
33409109 2020
25
A 35-Year-Old Smoker With Dyspnea and Chest Pain. 61
33280769 2020
26
Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile. 61
32860983 2020
27
Ileus, Gastrointestinal Bleeding and Clostridium difficile Colitis after Hip and Knee Replacement - a Systematic Review. 61
33137840 2020
28
Intracolonic Administration of Vancomycin in Intensive Care Unit Patients with Severe Clostridium Difficile Colitis. 61
33364098 2020
29
Additional prophylactic antibiotics do not decrease surgical site infection rates in pediatric patients with appendicitis and cholecystitis. 61
33248681 2020
30
The A2B trial, antibiotic prophylaxis for excision-graft surgery in burn patients: a multicenter randomized double-blind study. 61
33239101 2020
31
The mechanisms and safety of probiotics against toxigenic clostridium difficile. 61
32520637 2020
32
Diverting Loop Ileostomy for Clostridium Difficile Colitis: A Systematic Review and Meta-analysis. 61
33284670 2020
33
Transanal total mesorectal excision (taTME) for rectal cancer: beyond the learning curve. 61
31602515 2020
34
Microbiota in Clostridioides difficile-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections. 61
32911854 2020
35
Severe Clostridium difficile colitis as potential late complication associated with COVID-19. 61
32803988 2020
36
A systematic review and meta-analysis of diverting loop ileostomy versus total abdominal colectomy for the treatment of Clostridium difficile colitis. 61
32556579 2020
37
Meta-analysis of Postoperative Mortality and Morbidity After Total Abdominal Colectomy Versus Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis. 61
33044807 2020
38
Pseudomembranous Colitis at Colostomy Site. 61
32898708 2020
39
Clostridium difficile Infection in a Very Young Infant with Pseudomembranous Colitis Noted on Endoscopy. 61
33250692 2020
40
Relevance of proton pump inhibitors prescriptions in a tertiary care hospital in Lebanon. 61
32830092 2020
41
Evaluation of inpatients Clostridium difficile prevalence and risk factors in Cameroon. 61
32867842 2020
42
Salicylanilide Analog Minimizes Relapse of Clostridioides difficile Infection in Mice. 61
32482070 2020
43
Colon Involvement in Necrotizing Pancreatitis: Incidence, Risk Factors, and Outcomes. 61
32649468 2020
44
[Fecal microbiota transplants in the treatment of pseudomembranous colitis (1958-2013): priority of discovery and thought styles in the academic literature]. 61
33111793 2020
45
Successful Treatment of Pseudomembranous Colitis with Fecal Microbiota Transplantation - A Case Study on A Patient Rescued by Extracorporeal Cardiopulmonary Resuscitation After Cardiac Arrest. 61
32657282 2020
46
Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015. 61
32393487 2020
47
Hidradenitis suppurativa and risk for development of Clostridium difficile colitis. 61
32010962 2020
48
Colorectal Surgical Site Infection Prevention Kits Prior to Elective Colectomy Improve Outcomes. 61
30688687 2020
49
Neutropenic Enterocolitis Secondary to Sulfasalazine in a Woman With Psoriatic Arthritis. 61
32670712 2020
50
Live Birth Following Uterine Transplantation From a Nulliparous Deceased Donor. 61
32541565 2020

Variations for Clostridium Difficile Colitis

Expression for Clostridium Difficile Colitis

Search GEO for disease gene expression data for Clostridium Difficile Colitis.

Pathways for Clostridium Difficile Colitis

Pathways related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 STAT5A RHOQ RHOD RHOB RHOA IL1B
2
Show member pathways
13.16 RHOD RHOB RHOA NECTIN3 IL1B CDC42
3
Show member pathways
12.87 RHOQ RHOD RHOBTB1 RHOB RHOA CDC42
4
Show member pathways
12.84 RHOQ RHOD RHOB RHOA CDC42
5
Show member pathways
12.78 RHOQ RHOD RHOB RHOA NECTIN3 CDC42
6
Show member pathways
12.7 RHOQ RHOD RHOBTB1 RHOB RHOA CDC42
7
Show member pathways
12.67 STAT5A RHOD RHOB RHOA CDC42 CCR6
8
Show member pathways
12.56 STAT5A RHOD RHOB RHOA IL1B CDC42
9
Show member pathways
12.42 STAT5A RHOD RHOB RHOA CDC42
10
Show member pathways
12.29 STAT5A RHOD RHOB RHOA CDC42
11
Show member pathways
12.17 STAT5A RHOA LEPR IL1B CDC42
12 11.75 RHOB RHOA CDC42
13 11.75 RHOB RHOA IL1B CDC42
14
Show member pathways
11.73 RHOD RHOB RHOA PARP1 CDC42
15 11.63 RHOD RHOB RHOA CDC42
16 11.6 RHOA NECTIN3 CDC42
17 11.55 STAT5A RHOA CDC42
18 11.5 RHOD RHOB RHOA CDC42
19 11.4 RHOD RHOB RHOA
20 11.4 STAT5A RHOA LEPR
21 10.85 RHOD RHOB RHOA CDC42
22 10.64 RHOA CDC42
23 10.54 RHOB RHOA

GO Terms for Clostridium Difficile Colitis

Cellular components related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.47 RHOQ RHOD RHOBTB1 RHOB RHOA NECTIN3
2 cell cortex GO:0005938 9.26 RHOD RHOBTB1 RHOB RHOA

Biological processes related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell migration GO:0016477 9.83 RHOQ RHOD RHOB RHOA CDC42
2 regulation of cell shape GO:0008360 9.8 RHOQ RHOD RHOBTB1 RHOB RHOA
3 actin filament organization GO:0007015 9.77 RHOD RHOBTB1 RHOB RHOA CDC42
4 regulation of actin cytoskeleton organization GO:0032956 9.72 RHOQ RHOD RHOBTB1 RHOB RHOA
5 Rho protein signal transduction GO:0007266 9.65 RHOD RHOB RHOA
6 regulation of small GTPase mediated signal transduction GO:0051056 9.63 RHOQ RHOD RHOBTB1 RHOB RHOA CDC42
7 cortical cytoskeleton organization GO:0030865 9.56 RHOD RHOBTB1 RHOB RHOA
8 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.49 ATP4A ATP12A
9 negative regulation by host of viral process GO:0044793 9.46 LTF CRP
10 establishment or maintenance of cell polarity GO:0007163 9.35 RHOD RHOBTB1 RHOB RHOA CDC42
11 small GTPase mediated signal transduction GO:0007264 9.1 RHOQ RHOD RHOBTB1 RHOB RHOA CDC42

Molecular functions related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 10.03 RHOQ RHOD RHOBTB1 RHOB RHOA CDC42
2 protein kinase binding GO:0019901 9.73 RHOD RHOBTB1 RHOB RHOA PARP1 CDC42
3 GTP binding GO:0005525 9.43 RHOQ RHOD RHOBTB1 RHOB RHOA CDC42
4 sodium:potassium-exchanging ATPase activity GO:0005391 9.4 ATP4A ATP12A
5 potassium-transporting ATPase activity GO:0008556 9.37 ATP4A ATP12A
6 potassium:proton exchanging ATPase activity GO:0008900 9.32 ATP4A ATP12A
7 GBD domain binding GO:0032427 9.16 RHOQ CDC42
8 GTPase activity GO:0003924 9.1 RHOQ RHOD RHOBTB1 RHOB RHOA CDC42

Sources for Clostridium Difficile Colitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....